ClinicalTrialsFinder

RecruitingPhase 2NCT07516925

A Study of Ivonescimab in People With Leiomyosarcoma

Vonescimab for the Treatment of Previously Treated Advanced or Unresectable Leiomyosarcoma - a Phase II Trial

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

20 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ivonescimab for people with leiomyosarcoma. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIvonescimab

Ivonescimab is administered IV Q3W on Day 1 of each cycle

Locations(7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Rockville Centre, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT07516925

Related Trials

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

NCT069752939 locations

Localized Leiomyosarcoma Biomarker Protocol

NCT049250893 locations

Metastatic Leiomyosarcoma Biomarker Protocol

NCT0565338811 locations

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT0678917210 locations

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

NCT076286341 location